The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health - Bedimo, Roger J.; Drechsler, Henning; Jain, Mamta; Cutrell, James; Zhang, Song; Li, Xilong; Farukhi, Irfan; Castanon, Rosinda; Tebas, Pablo; Maalouf, Naim M. (PloS one, 2014)
Keywords: Acquired immune deficiency syndrome; Adenine - administration & dosage; Adenine - analogs & derivatives; Adult; AIDS; Antiretroviral agents; Antiretroviral drugs; Biology and Life Sciences; Bone (long); Bone density; Bone Density - drug effects; Bone mineral density; Bone turnover; CD4 antigen; Chi-square test; Cholesterol; Collagen; Darunavir; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Dual energy X-ray absorptiometry; Effectiveness; Emtricitabine; Epidermal growth factor receptors; High density lipoprotein; HIV; HIV Infections - drug therapy; HIV Infections - metabolism; HIV Infections - pathology; HIV-1; Human immunodeficiency virus; Humans; Lipoproteins (high density); Long bone; Markers; Medicine and health sciences; Middle Aged; Mitochondria; Motivation; Organophosphonates - administration & dosage; Patients; Pyrrolidinones - administration & dosage; Radar; Raltegravir Potassium; Ritonavir; Statistical tests; Sulfonamides - administration & dosage; Tenofovir; Toxicity; United States--US; Texas